Poolbeg Pharma plc - Agreement signed for MelioVac with University College Dublin

Jeremy Skillington, CEO of Poolbeg Pharma and Cathal Friel tell us about the recently signed option agreement with University College Dublin for a Melioidosis Vaccine candidate, MelioVac, and a licence to evaluate 5 other infectious disease portfolio assets.

Cathal Friel
Chairman
Jeremy Skillington
Chief Executive Officer

Company Events - POOLBEG PHARMA